Emerson (EMR) Q2 2026 earnings review
Resilient Margins Mask Sluggish Core Sales
Emerson delivered a mixed Q2 2026, as top-line growth decelerated sharply to 3% reported (0.5% underlying) from 4.1% in Q1. The slowdown was heavily influenced by the Middle East conflict, dragging Asia/MEA sales down 5%. Despite sluggish revenue, profitability held stable—Adjusted Segment EBITA margin dipped only 40 bps to 27.6%, and Adjusted EPS rose 4% to $1.54. Looking ahead, management expects an acceleration, guiding for ~5.5% sales growth in Q3 and returning ~$2.2B to shareholders in FY26.
🐂 Bull Case
The T&M segment remains a powerful growth engine, accelerating with 16% reported and 12% underlying sales growth in Q2, proving the success of recent integrations.
Underlying orders (excluding AspenTech) grew 5% in Q2, providing confidence in the guided revenue acceleration for the second half of FY26.
🐻 Bear Case
Underlying sales for Intelligent Devices fell 1%, and Control Systems & Software fell 2%. T&M cannot single-handedly offset weakness in Emerson's legacy automation core.
The ongoing Middle East conflict actively suppressed sales this quarter, dragging the entire Asia, Middle East & Africa region down 5%.
⚖️ Verdict: ⚪
Neutral. Strong margin defense and a booming T&M segment are currently offsetting tangible weakness in core automation and geopolitical headwinds, but the reliance on H2 acceleration adds execution risk.
Key Themes
Test & Measurement Leads the Charge
Test & Measurement was the undisputed star of Q2, accelerating to 12% underlying sales growth ($414M). Even more impressively, its Adjusted EBITA margin expanded from 24.3% to 26.3% YoY. This validates management's prior narrative of a sharp discrete market recovery and successful synergy realization from the NI acquisition.
Core Automation Reversing to Contraction
A notable red flag emerged in Emerson's largest segments. Intelligent Devices (Final Control and Sensors) saw underlying sales reverse to -1% YoY. Similarly, Control Systems & Software contracted by 2% underlying. If the core industrial automation engine continues to stall, it will jeopardize the company's long-term $21B revenue targets.
Geopolitical Headwinds Materialize
Management explicitly cited the conflict in the Middle East as a drag on Q2 sales. The financial impact is visible in the regional breakdown: sales in Asia, Middle East & Africa declined 5% YoY. Europe also remained weak, declining 4%.
Aggressive Capital Returns Provide Floor
Emerson's balance sheet execution remains robust. Despite Free Cash Flow decelerating 6% YoY to $694M in Q2, the company reaffirmed its massive FY26 capital return framework. Management expects to return ~$2.2B to shareholders, comprising ~$1B in share repurchases and ~$1.2B in dividends, highlighting confidence in forward cash generation.
Other KPIs
Stable. Only a slight 40 bps deceleration from 28.0% in 25Q2. The ability to maintain high margins despite essentially flat underlying sales growth (0.5%) highlights strong operational leverage and cost control.
Reversing. Down 6% YoY from $825M in 25Q2, driven by a significant $613M drag from changes in operating working capital over the first six months of FY26. Elevated inventory ($2.45B, up from $2.21B at FY25 end) requires monitoring.
Guidance
Accelerating. Implies a sharp rebound from the 2.9% reported growth in Q2. Management expects 5% underlying growth, relying on the 5% Q2 underlying order growth to convert to revenue.
Accelerating. At the midpoint ($1.675), this implies a strong sequential and YoY acceleration compared to the $1.52 delivered in 25Q3, driven by volume leverage and share repurchases.
Stable. Reaffirmed guidance implies a healthy step up from the ~$3.2B generated in FY25, though the current working capital drag means H2 must execute flawlessly to hit the target.
Key Questions
Middle East Deferral vs Destruction
You noted the Middle East conflict impacted Q2 sales. Is this revenue permanently lost, or deferred to the second half? What is baked into the ~5.5% Q3 guide regarding this region?
Core Segment Weakness
Intelligent Devices and Control Systems underlying sales turned negative this quarter. How much of this is project timing versus underlying end-market weakness, particularly in Discrete and Chemical markets?
Working Capital Drag
Operating Cash Flow fell 6% YoY due to working capital changes, and inventory is up roughly $240M since fiscal year-end. What is driving this buildup, and when do you expect it to normalize?